- Home
- AMKR vs IONS Comparison
AMKR vs IONS Comparison
Compare AMKR & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMKR
- IONS
- Stock Information
- Founded
- AMKR 1968
- IONS 1989
- Country
- AMKR United States
- IONS United States
- Employees
- AMKR N/A
- IONS N/A
- Industry
- AMKR Semiconductors
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- AMKR Technology
- IONS Health Care
- Exchange
- AMKR Nasdaq
- IONS Nasdaq
- Market Cap
- AMKR 6.5B
- IONS 6.0B
- IPO Year
- AMKR 1998
- IONS 1991
- Fundamental
- Price
- AMKR $26.54
- IONS $34.01
- Analyst Decision
- AMKR Buy
- IONS Buy
- Analyst Count
- AMKR 9
- IONS 18
- Target Price
- AMKR $36.13
- IONS $62.00
- AVG Volume (30 Days)
- AMKR 1.6M
- IONS 1.4M
- Earning Date
- AMKR 10-28-2024
- IONS 11-06-2024
- Dividend Yield
- AMKR 1.19%
- IONS N/A
- EPS Growth
- AMKR N/A
- IONS N/A
- EPS
- AMKR 1.48
- IONS N/A
- Revenue
- AMKR $6,440,385,000.00
- IONS $803,067,000.00
- Revenue This Year
- AMKR N/A
- IONS N/A
- Revenue Next Year
- AMKR $7.02
- IONS $16.31
- P/E Ratio
- AMKR $17.94
- IONS N/A
- Revenue Growth
- AMKR N/A
- IONS 30.57
- 52 Week Low
- AMKR $24.10
- IONS $33.33
- 52 Week High
- AMKR $44.86
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- AMKR 44.57
- IONS 32.90
- Support Level
- AMKR $25.02
- IONS $33.33
- Resistance Level
- AMKR $28.43
- IONS $35.65
- Average True Range (ATR)
- AMKR 0.65
- IONS 1.55
- MACD
- AMKR 0.10
- IONS -0.36
- Stochastic Oscillator
- AMKR 44.74
- IONS 10.09
About AMKR Amkor Technology Inc.
Amkor Technology Inc is a provider of outsourced semiconductor packaging and test services to integrated device manufacturers, fabless semiconductor companies, and contract foundries. The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.